Comtan®

DRUG4 trials

Sponsors

Bial - Portela C S.A.

Conditions

Parkinson DiseaseParkinson's Disease (PD)

Phase 1

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

CompletedNCT03091868

Bial - Portela C S.A.Parkinson Disease

Start: 2004-11-03End: 2005-02-28Updated: 2017-03-27

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

CompletedNCT03094156

Bial - Portela C S.A.Parkinson Disease

Start: 2006-04-26End: 2006-07-11Updated: 2017-03-30

Phase 2

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

CompletedNCT02834507

Bial - Portela C S.A.Parkinson's Disease (PD)

Start: 2005-03-31End: 2005-11-30Updated: 2016-07-15

Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon

CompletedNCT03103399

Bial - Portela C S.A.Parkinson Disease

Start: 2006-09-26End: 2007-09-21Updated: 2017-04-06